Regulated Healthcare. Disciplined Capital. Long-term Partnerships.
We are a healthcare platform focused on partnering with and acquiring best-in-class 503A compounding pharmacies, providing long-term succession solutions while supporting continued clinical independence, regulatory rigor, and sustainable growth. Backed by experienced operators, regulators, and capital markets professionals, we bring institutional capital, operational infrastructure, and strategic support to a highly fragmented industry creating a credible, scalable platform for pharmacists, investors, and financing partners alike.
Who We Partner With
We partner with... pharmacists who take a long-term view.
We work with independent 503A compounding and retail/compounding pharmacies that have built trusted clinical relationships, strong compliance cultures, and durable local reputations. Our partnerships are grounded in professionalism, regulatory integrity, and alignment over time.
For entrepreneurial pharmacists, we seek operators who want to play a broader role in building a high-quality platform. These partners are motivated by growth, operational excellence, and the opportunity to help shape the next generation of compounding pharmacy while remaining closely connected to patient care and clinical decision-making.
We value... operators who want responsibility, not just ownership.
For founder-owners considering succession, we offer a thoughtful transition path that prioritizes liquidity, continuity, and stability. In many cases, this includes a period of continued involvement, supporting patients, staff, and prescriber relationships as the business enters its next phase.
We respect... what has been built.
Across both groups, we are selective. We partner with pharmacists who value compliance, ollaboration, and consistency, and who understand that durable outcomes in healthcare are built through trust, discipline, and shared standards.
This approach is not right for every situation, and that is intentional.
Our Approach
Our approach... is deliberately selective and long term.
We take a disciplined view of ownership in a highly regulated healthcare environment, focusing on stability, alignment, and durable value rather than short-term optimization or rapid expansion.
We believe lasting value in compounding pharmacy is created by pairing strong local operators with consistent standards in governance, compliance, and capital stewardship. This requires patience, selectivity, and respect for the regulatory responsibilities that underpin personalized medicine.
We prioritize... durability over speed.
Our role as an owner is to provide stability, resources, and strategic support, while allowing pharmacists to remain focused on clinical excellence and patient care. Consistency in decision-making and standards is essential to maintaining trust with patients, prescribers, regulators, and financial partners.
We do not... pursue growth that compromises compliance or reputation.
Capital is deployed thoughtfully, with emphasis on risk management, regulatory integrity, and long-term sustainability. Growth is pursued only where it reinforces quality and resilience.
Above all, our approach is built for longevity creating a platform pharmacists are proud to be part of and that investors and lenders can underwrite with confidence over a multi-year horizon.
Jeffrey N. Gibbs
BA, JDRegulatory & Compliance Advisor
Jeffrey Gibbs is a leading FDA regulatory attorney with more than four decades of experience advising life sciences companies on regulatory, compliance, and enforcement matters. His practice has spanned drugs, biologics, medical devices, and compounding pharmacies, with particular expertise in FDA enforcement, regulatory strategy, and agency interactions.
Mr. Gibbs previously served as Associate Chief Counsel for Enforcement at the U.S. Food and Drug Administration and has been a key part of one of the premier FDA practices in the United States. He has extensive experience advising compounding pharmacies and related industry participants on regulatory compliance, inspections, and enforcement risk.
Mr. Gibbs is widely recognized as a top FDA regulatory lawyer and has held multiple leadership roles within the Food and Drug Law Institute, including Chairman. He holds a J.D. from New York University School of Law and a B.A. from Princeton University.
Torben Luth
BA, MBACapital Markets Advisor
Torben Luth is a private equity investment professional with more than 20 years of experience across the European lower middle market, spanning investment activity, portfolio management, and business development. He is experienced in identifying attractive sectors, originating and closing transactions, leading due diligence, arranging financing, and supporting management teams through strategic and operational inflection points.
Mr. Luth also brings practical experience in team building, growth planning, and buy-and-build execution across a range of industries. Earlier in his career, he was an entrepreneur in a manufacturing business and also served as a representative of the Danish Ministry of Commerce in the United States.
He will advise Elev8Rx on capital strategy, investor positioning, incentive alignment, and broader private equity and capital markets considerations as the platform grows.
Darren Youngleson
BAcc, BCom, MBAIntegration Advisor
Darren Youngleson is an experienced healthcare executive and advisor with a strong track record in scaling, integrating, and advising healthcare businesses across multiple stages of growth. His career includes leadership, board, and advisory roles across healthcare services and investment-backed businesses, with meaningful experience in mergers and acquisitions, post-acquisition integration, and strategic business transformation.
Mr. Youngleson brings particular strength in integrating acquired businesses, aligning management teams, preserving culture, and executing through periods of transition. His experience spans both operating and board-level roles, giving him a practical perspective on the organizational and execution challenges that often determine whether an acquisition is ultimately successful.
He will advise Elev8Rx on seller transition, management alignment, and post-acquisition integration as the platform expands.
Bruce F. Mackler
BA, MS, PhD, JDFDA Regulatory & Formulary Advisor
Bruce Mackler is a highly experienced FDA legal and regulatory advisor with more than 35 years of experience across drugs, biologics, nutraceuticals, medical devices, and other biomedical products. His expertise spans FDA regulatory strategy, product development, manufacturing and quality oversight, and investor-facing regulatory due diligence.
Dr. Mackler has advised both operating companies and financial sponsors on FDA strategy, regulatory diligence, and commercialization considerations. He has also served in senior executive and advisory roles at multiple biomedical companies, including as CEO, President, COO, and Vice President of Regulatory Affairs.
Earlier in his career, Dr. Mackler built a substantial scientific foundation as an immunology and microbiology researcher and has authored more than 100 scientific papers and abstracts. He holds a J.D. from South Texas College of Law, a Ph.D. from the University of Oregon Medical School, an M.S. from Pennsylvania State University, and a B.A. from Temple University.
Contact Us
We welcome confidential inquiries
from pharmacy owners and
investment partners seeking a
thoughtful, expierenced partner.
All outreach is handled drescreetly.